Analyst Research and Recommendations: Array BioPharma Inc. (ARRY), BofI Holding, Inc. (BOFI)

Nj State Employees Deferred Compensation Plan owns 60,000 shares or 0.1% of their USA portfolio. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Array BioPharma during the second quarter valued at $110,000. Td Asset Mgmt Inc, a Ontario – Canada-based fund reported 107,868 shares.

Research analysts at SunTrust Banks decreased their FY2018 earnings per share (EPS) estimates for Array BioPharma in a research report issued on Wednesday. Millennium Mgmt Ltd reported 1.85 million shares or 0.03% of all its holdings. Putnam Invests Llc holds 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY) for 225,763 shares. Hightower Ltd Liability accumulated 0% or 10,750 shares. 1,678 are held by Federated Invsts Pa. Stifel Finance Corp accumulated 19,145 shares or 0% of the stock.

The average Wall Street analyst rating for Array BioPharma Strong Buy, according to the average of 9 analyst scores. Therefore 75% are positive. The lowest target is $9.0 while the high is $13.0. Array Biopharma Inc (NASDAQ:ARRY)’s price sits 2.66% above from its 50-day moving average of $8.26 and -5.17% away from the stock’s 200-day moving average which is $9.1. Leerink Swann maintained the stock with “Outperform” rating in Monday, September 26 report. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. Finally, Piper Jaffray Companies set a $14.00 target price on Array BioPharma and gave the company a “buy” rating in a report on Wednesday, May 31st. Array BioPharma has an average rating of “Buy” and an average target price of $11.54. Evercore initiated the shares of MBLY in report on Wednesday, December 2 with “Buy” rating. The rating was maintained by Barclays Capital with “Equal-Weight” on Friday, August 4. Cowen & Co has “Buy” rating and $1400 target. Rhumbline Advisers stated it has 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY). 45,000 shares were sold by LEFKOFF KYLE, worth $401,400 on Friday, March 31. ARRY is down around 62.83% from its 12-month high of $3.1 notched on Aug 25, 2016 but is -60.67% above its highest point the past 12 months of $13.4 a share.

It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The corporation has a market cap of US$1.37 Billion. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib. A negative earnings surprise will usually result in a decline in share price. The Company’s binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC).

Investors sentiment decreased to 1.3 in Q4 2016. Its the same as in 2016Q3.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Its up 0.27, from 0.33 in 2016Q3. Amer Gru Inc accumulated 7,830 shares. Amalgamated Bankshares reported 0.01% in Pra Group Inc (NASDAQ:PRAA). Macquarie Gp holds 330,000 shares. Amer Intl Grp has 83,069 shares for 0% of their portfolio. Jpmorgan Chase & holds 0% of its portfolio in Carbonite Inc (NASDAQ:CARB) for 98,855 shares. The Minnesota-based Jnba Fincl Advsrs has invested 0% in Pra Group Inc (NASDAQ:PRAA). The profitability rank of the company is 2 (out of 10). Its up 4.73% from 20.07 million shares previously. Blackrock Fund has invested 0% in Graham Corporation (NYSE:GHM). Moreover, Cap Management Assocs has 0.55% invested in Constellation Brands, Inc. Similarly, full-year sales forecasts have ranged between $130.1 Million and $150.4 Million. Ansys Inc (NASDAQ:ANSS) was reduced too.

Among 4 analysts covering Portfolio Recovery Associates (NASDAQ:PRAA), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 32% are positive. Portfolio Recovery Associates had 8 analyst reports since October 14, 2015 according to SRatingsIntel. The stock of Constellation Brands, Inc. RBC Capital Markets maintained it with “Outperform” rating and $68 target in Thursday, July 30 report.